The prognostic effect of TTF-1 expression in the Chinese population of patients with advanced lung adenocarcinomas.
Thyroid transcription factor 1 (TTF-1)
lung adenocarcinomas
pemetrexed
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
25
3
2020
pubmed:
25
3
2020
medline:
25
3
2020
Statut:
ppublish
Résumé
Thyroid transcription factor 1 (TTF-1), which is usually expressed by lung adenocarcinomas and small cell carcinomas, is usually used to distinguish adenocarcinoma and small cell carcinoma from cells of another type of lung cancer. We examined the association between TTF-1 expression and overall survival between patients with stage IV pulmonary adenocarcinoma to investigate the role of TTF-1 as a predictive and/or prognostic tumor marker in patients with advanced lung adenocarcinomas. Analysis of the clinicopathologic features, treatment regimens, and overall survival of 209 lung adenocarcinoma patients who had been detected for TTF-1 expression and received consecutive treatments in the Affiliated Hospital of Qingdao University. TTF-1 expression was positive in 166 (79%) and negative in 43 (21%) patients who were reviewed. Moreover, there was no significant difference between the clinicopathologic features of TTF-1 positive and TTF-1 negative tumors. In the multivariable review, the overall survival of TTF-1 positive tumor patients was significantly longer than that of TTF-1 negative tumor patients [22.7 TTF-1 expression was associated with an improved survival in patients with advanced lung adenocarcinomas. Both patients, either TTF-1 positive or negative, could benefit from the first-line chemotherapy or pemetrexed treatment option. However, as discovered by our investigation, TTF-1 cannot forecast a portion of the lung adenocarcinomas that had a selective sensitivity to pemetrexed.
Sections du résumé
BACKGROUND
BACKGROUND
Thyroid transcription factor 1 (TTF-1), which is usually expressed by lung adenocarcinomas and small cell carcinomas, is usually used to distinguish adenocarcinoma and small cell carcinoma from cells of another type of lung cancer. We examined the association between TTF-1 expression and overall survival between patients with stage IV pulmonary adenocarcinoma to investigate the role of TTF-1 as a predictive and/or prognostic tumor marker in patients with advanced lung adenocarcinomas.
METHODS
METHODS
Analysis of the clinicopathologic features, treatment regimens, and overall survival of 209 lung adenocarcinoma patients who had been detected for TTF-1 expression and received consecutive treatments in the Affiliated Hospital of Qingdao University.
RESULTS
RESULTS
TTF-1 expression was positive in 166 (79%) and negative in 43 (21%) patients who were reviewed. Moreover, there was no significant difference between the clinicopathologic features of TTF-1 positive and TTF-1 negative tumors. In the multivariable review, the overall survival of TTF-1 positive tumor patients was significantly longer than that of TTF-1 negative tumor patients [22.7
CONCLUSIONS
CONCLUSIONS
TTF-1 expression was associated with an improved survival in patients with advanced lung adenocarcinomas. Both patients, either TTF-1 positive or negative, could benefit from the first-line chemotherapy or pemetrexed treatment option. However, as discovered by our investigation, TTF-1 cannot forecast a portion of the lung adenocarcinomas that had a selective sensitivity to pemetrexed.
Identifiants
pubmed: 32206556
doi: 10.21037/tlcr.2019.12.29
pii: tlcr-09-01-82
pmc: PMC7082290
doi:
Types de publication
Journal Article
Langues
eng
Pagination
82-89Informations de copyright
2020 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Clin Chim Acta. 2015 Dec 7;451(Pt B):208-14
pubmed: 25661085
Cancer Discov. 2013 Jun;3(6):630-5
pubmed: 23533264
Hum Pathol. 2004 Jan;35(1):3-7
pubmed: 14745718
Ann Oncol. 2016 Jul;27(7):1286-91
pubmed: 27056998
Chest. 2012 Feb;141(2):420-428
pubmed: 21799026
Mod Pathol. 2011 Oct;24(10):1348-59
pubmed: 21623384
Lung Cancer. 2006 May;52(2):219-24
pubmed: 16545887
J Thorac Oncol. 2011 Aug;6(8):1392-9
pubmed: 21716147
J Thorac Oncol. 2009 Aug;4(8):951-8
pubmed: 19543119
Ann Transl Med. 2018 Apr;6(8):142
pubmed: 29862231
J Clin Pathol. 2004 Apr;57(4):383-7
pubmed: 15047742
J Cell Mol Med. 2009 Aug;13(8B):1977-1986
pubmed: 19040416
J Pathol. 2004 Sep;204(1):101-9
pubmed: 15307143
Hum Pathol. 2003 Jun;34(6):597-604
pubmed: 12827614
Cancer. 2012 Jun 1;118(11):2889-99
pubmed: 22020674
Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):103-9
pubmed: 12051626
Clin Cancer Res. 2011 Apr 15;17(8):2434-43
pubmed: 21257719
Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S334-S335
pubmed: 30705848
Cancer Cell. 2012 Mar 20;21(3):348-61
pubmed: 22439932
J Thorac Oncol. 2016 Jul;11(7):1140-52
pubmed: 27094798
Br J Cancer. 2005 Aug 22;93(4):450-2
pubmed: 16052216
Am J Surg Pathol. 2001 Mar;25(3):363-72
pubmed: 11224607
Ann Surg Oncol. 2013 Sep;20(9):3015-22
pubmed: 23525704
J Clin Oncol. 2009 Jan 10;27(2):271-8
pubmed: 19064983
Transl Cancer Res. 2019 Oct;8(6):2223-2229
pubmed: 35116975
J Thorac Oncol. 2012 Jan;7(1):76-84
pubmed: 22011671
J Clin Invest. 2012 Dec;122(12):4388-400
pubmed: 23143308
Lung Cancer. 2009 Apr;64(1):105-9
pubmed: 18801593
Nature. 2007 Dec 6;450(7171):893-8
pubmed: 17982442
Lancet Oncol. 2016 May;17(5):642-50
pubmed: 27080216
Lung Cancer. 2003 Jan;39(1):31-6
pubmed: 12499091
J Korean Med Sci. 2003 Aug;18(4):494-500
pubmed: 12923324
Lung Cancer. 2017 Jun;108:205-211
pubmed: 28625636